Product Details for NDA 211913
ABSORICA LD (ISOTRETINOIN)
8MG
Marketing Status: Prescription
16MG
Marketing Status: Prescription
24MG
Marketing Status: Prescription
32MG
Marketing Status: Prescription
20MG
Marketing Status: Discontinued
28MG
Marketing Status: Discontinued
8MG
Marketing Status: Prescription
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 8MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 001
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
ABSORICA LD (ISOTRETINOIN)
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 8MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 001
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
16MG
Marketing Status: Prescription
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 16MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 002
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
ABSORICA LD (ISOTRETINOIN)
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 16MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 002
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
24MG
Marketing Status: Prescription
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 24MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 004
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
ABSORICA LD (ISOTRETINOIN)
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 24MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 004
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
32MG
Marketing Status: Prescription
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 32MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N211913
Product Number: 006
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
ABSORICA LD (ISOTRETINOIN)
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 32MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N211913
Product Number: 006
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Prescription
Patent and Exclusivity Information
20MG
Marketing Status: Discontinued
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 20MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 003
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Discontinued
Patent and Exclusivity Information
ABSORICA LD (ISOTRETINOIN)
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 20MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 003
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Discontinued
Patent and Exclusivity Information
28MG
Marketing Status: Discontinued
Active Ingredient: ISOTRETINOIN
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 28MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 005
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: ABSORICA LD
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 28MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N211913
Product Number: 005
Approval Date: Nov 5, 2019
Applicant Holder Full Name: SUN PHARMACEUTICAL INDUSTRIES LTD
Marketing Status: Discontinued
Patent and Exclusivity Information